New‐onset heart failure in the STOP‐HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure

2020 ◽  
Vol 22 (2) ◽  
pp. 378-380 ◽  
Author(s):  
Sarah McClelland ◽  
Shuaiwei Zhou ◽  
Eoin O'Connell ◽  
Joseph Gallagher ◽  
Fiona Ryan ◽  
...  
2011 ◽  
Vol 107 (5) ◽  
pp. 723-729 ◽  
Author(s):  
Krista C. van den Broek ◽  
Christopher R. deFilippi ◽  
Robert H. Christenson ◽  
Stephen L. Seliger ◽  
John S. Gottdiener ◽  
...  

2018 ◽  
Vol 45 (04) ◽  
pp. 129-134
Author(s):  
I.-Ping Chan ◽  
Tung Hsueh ◽  
Wen-Ying Chen

Two 8-year-old small-breed neutered dogs were referred due to respiratory distress caused by a new onset of congestive heart failure secondary to degenerative mitral valve disease. Medical treatment, including a diuretic and a vasodilator, was initiated, and blood samples for evaluating the levels of blood urea nitrogen, creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were collected at every visit. The two dogs had entirely different outcomes: one is still alive with its symptoms well controlled by the medications, whereas the other one was unstable during the therapeutic period and only survived for 89 days after the diagnosis was made. Serial measurements of NT-proBNP concentration revealed that its gradual decline corresponded to better outcome, whereas fluctuant and ascending concentrations reflected a poor prognosis.


Sign in / Sign up

Export Citation Format

Share Document